『2 Minutes with Joey - TMO Stock News』のカバーアート

2 Minutes with Joey - TMO Stock News

2 Minutes with Joey - TMO Stock News

著者： 2 Minutes with Joey
無料で聴く

Two minutes with Joey on Thermo Fisher Scientific (TMO) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey 社会科学
エピソード
  • TMO Today - Aug 13: Mixed Signals from Investors

    TMO Today - Aug 13: Mixed Signals from Investors
    2026/08/13
    Hey there! It's Joey here, your friendly longtime investor breaking down the day. Today, we’re talking about Thermo Fisher Scientific, and it was a bit of a red day for them. They dipped just a tiny bit, down 0.17%.

    So, what went down? Honestly, it was a pretty quiet day overall. The trading volume was right on average, so not much frenzy happening. It seems investors were a bit split on their feelings about TMO. Some folks decided to cut back on their shares, like Y Intercept and Howland Capital, while others, like Magellan Asset Management, jumped in and added more to their positions. Kind of a mixed bag, you know?

    Now, why the mixed signals? Well, there’s buzz around Thermo Fisher’s recent Q2 earnings where they beat estimates by a whopping $300 million. That’s a big win! But then you’ve got the sale of their microbiology unit to Astorg, which is a major shift for the company. Some investors are probably feeling a little uncertain about how that’ll play out. So, it’s like one step forward, one step back.

    Also, there’s chatter about their stock position changes. Some are scaling back, and others are upping their game. It's interesting to see how different investors are reading the tea leaves on this one.

    Looking ahead, Thermo Fisher recently closed that sale of the microbiology unit, which is a big deal. It could mean a whole new direction for them, and investors are definitely keeping an eye on what that means for the future.

    So, that’s the scoop for today! Thermo Fisher is navigating some ups and downs, and it’s clear folks are weighing their options. Remember, I'm just sharing info and having a good time talking stocks, so take this as entertainment and not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • TMO Today - Aug 12: FDA news and insider selling

    TMO Today - Aug 12: FDA news and insider selling
    2026/08/12
    Hey there! It’s Joey, your friendly longtime investor, here to break down today’s action on Thermo Fisher Scientific, or TMO for short. Today was a bit of a bummer—it ended in the red, down about 1.3%.

    So, what happened? The stock got hit with a small drop, losing a bit of its value. Not a huge shakeup, but still, nobody likes to see their stocks go down, right? The volume was pretty standard, so it wasn’t like a panic sell-off or anything wild.

    Now, why did this happen? Well, there’s a mix of stuff going on. First off, there was some chatter about a new FDA-cleared platform for treating multiple myeloma. Sounds fancy, right? But it seems like investors are still trying to process what that actually means for the company long-term. Mixed reactions are always a thing in the market, and this one’s no exception.

    On top of that, we had some insider selling today. The VP of Thermo Fisher sold around $245K worth of stock, and the CEO also exercised some options and sold almost 5,000 shares. It’s like, when the big dogs are cashing in, it raises a few eyebrows. People might think, “Do they know something we don’t?” It’s not always a bad sign, but it definitely makes folks a bit uneasy.

    Also, on the buying side, Hudson Value Partners and Northside Capital Management both made moves to grab more shares of TMO. So, it’s not all doom and gloom—there’s still interest in the stock.

    Looking ahead, it’s worth keeping an eye on how that FDA news plays out. If the new platform gains traction, it could turn things around. But for now, it’s a bit of a waiting game.

    Alright, that’s the scoop on TMO today. Just remember, I’m here to share info and keep it real—not giving any financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • TMO Today - Aug 11: Mixed Reactions to FDA News

    TMO Today - Aug 11: Mixed Reactions to FDA News
    2026/08/11
    Hey there! It’s Joey here, your friendly longtime investor, breaking down the day for you. Today, we’re looking at Thermo Fisher Scientific, or TMO for short. It was kind of a mixed bag day, finishing just a smidge in the green, up a tiny 0.15%.

    So, what went down? Well, TMO barely moved, but there were some interesting things happening behind the scenes. The stock saw a bit of action with some big names selling off shares. The CEO, Marc Casper, sold a chunk of his stock—over 4,600 shares, which is a big deal. I mean, when the top dog is cashing out, it can raise some eyebrows, right? Then there’s Handelsbanken Fonder AB cutting back on their holdings too. Not exactly the confidence boost you want to see.

    But here’s where it gets interesting: Investors were buzzing about a new FDA clearance for TMO’s multiple myeloma platform. This is a major deal in the biotech world, and you’d think that would send the stock soaring. But instead, it felt like people were still weighing the news against those sell-offs. So, we got this weird vibe of excitement mixed with caution. That one stung a bit for some.

    Looking ahead, TMO’s got a lot on its plate, especially with the new product launch coming soon. It'll be interesting to see how that plays out and if it gets people feeling more positive about the stock.

    Alright, that’s the scoop for today! Just remember, this is all for your info and entertainment—no financial advice here. Catch you later!
    続きを読む 一部表示
    1 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません